Abbott Laboratories
I · Analiza AI
Pe scurt
Abbott makes and sells healthcare products worldwide across four main areas: generic pharmaceuticals for chronic conditions, laboratory diagnostic systems and rapid tests, infant formula and nutritional products for children and adults, and medical devices including heart valves, glucose monitors, and pacemakers [Yahoo Finance]. The company serves hospitals, clinics, pharmacies, and consumers in both developed and emerging markets.
Abbott Laboratories is a diversified healthcare giant operating across four major segments: established pharmaceuticals, diagnostic products, nutritional products, and medical devices [Yahoo Finance]. The company generates $44.3B in annual revenue with strong margins and minimal debt, earning a perfect 10.0/10 financial health score [Yahoo Finance]. Recent strategic moves include a $21B acquisition of cancer diagnostics firm Exact Sciences and a pivot toward volume-driven nutrition sales, though the nutrition division contracted 6% in early 2026 [Yahoo Finance].
Abbott maintains exceptionally strong financial health with minimal debt, robust cash generation, and consistent profitability.
Scor Sentinellis
10/10
Financially healthy
Capitalizare bursieră
$154.7B
Venituri (12 luni)
$44.3B
II · Știri recente
Ce a mișcat prețul
6 stories · ranked by relevance
- macro2026-05-20
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum
Yahoo Finance
- macro2026-05-18
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?
Yahoo Finance
- macro2026-05-19
Abbott Laboratories Insiders Added US$4.23m Of Stock To Their Holdings
Yahoo Finance
- macro2026-05-18
Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols
Yahoo Finance
- macro2026-05-18
Hepatic Cirrhosis Market Research and Forecast Report 2026-2036, Profiles of Abbott, Astellas Pharma, Gilead Sciences, Novartis, Takeda Pharma, Grifols Therapeutics, and Cellaion
Yahoo Finance
- macro2026-05-18
Wearables in Pharma & Biotech Research and Forecasts Report 2026-2031, Company Profiles and Market Strategies of Abbott, Dexcom, and Masimo
Yahoo Finance
Premium · gratuit cu orice cont
The nutrition division shrank 6% in early 2026 due to price increases that backfired by reducing customer purchases, loss of a major U.S. government contract for low-income family nutrition products, and persistently high raw material costs since the pandemic [Yahoo Finance]
Riscuri
4
Oportunități
6
Semnale de alarmă
2
Conducere
10
Încă 21 de constatări în raportul complet — gratuit cu orice cont.
Deblochează analiza completă Abbott Laboratories
Fă-ți un cont gratuit ca să vezi raportul complet generat de AI, cu surse citate în text.
- 4 riscuri, 6 oportunități și 2 semnale de alarmă — fiecare cu sursa lui
- Peste 100 de indicatori financiari, cu grafice și comparații
- Rezumate complete ale știrilor, cu linkuri către surse
- Echipa de conducere și remunerația
- Export PDF pentru citit offline
III · Companii similare
Ai putea citi și
Same sector · Healthcare or comparable health
Vrei compania asta pe lista ta?